trialsitenews's podcast

In the last few weeks, the mainstream media ran with stories about Ivermectin, most noticeably referring to it as "horse medicine" or "horse dewormer" while, for some reason, leaving out the fact that Ivermectin is a WHO essential medicine for HUMANS. At the same time, the mainstream media and social media ran with a specific story about Oklahoma hospitals having to turn away gunshot victims because of a surge of people overdosing on Ivermectin. The bombshell story turned out to be false, forcing magazines, like Rolling Stone, to issue a correction, but not before popular news outlets shared it widely on social media, without Big Tech's "disclaimer of shame" for spreading misinformation. Dr. Kory Responds.

An interview with Kelly McKee from Medidata on transforming the patient clinical trial experience.

Join the Conversation! | https://trialsitenews.com/ In the first edition of CATalyst, Shabnam Palesa Mohamed engages Advocate Dipali Ohja (IBA), Dr Pierre Kory (FLCCC), and Dr Tess Lawrie (EBMC) about the Indian Bar Association's decision to issue legal notice on WHO chief scientist, Dr Soumya Swaminathan. The 51 page notice, served 25th of May, claims as its legal basis alleged WHO's 'disinformation and censorship' on the Ivermectin issue. #CATalyst #TrialSiteNews #TrialSiteNewsAfrica #TSNA

We sit down with Ralph Lorigo, of the Law Office of Ralph C. Lorigo to discuss NY court cases regarding Ivermectin and Covid-19. His firm have represented a number of elderly patients who have taken on their respective hospitals who refused to continue to administer doctor prescribed Ivermectin for the treatment Covid-19. This episode does not discuss the efficacy of the drug in relation to the virus, but rather, the legal fight surrounding it. Watch the video to hear the whole story! Join The Conversation, Visit us at: www.trialsitenews.com Check out the Law Office Of Ralph C. Lorigo: https://www.lorigo.com/

Shabnam Palesa Mohamed: Activist. journalist, mediator (LLB). Founder of SAHARI and THJ CEO, discusses state of Ivermectin in South Africa. We discuss the twists and turns of the legality issues of the drug, to a campaign to bring awareness through-out the country and beyond. Petition Link: https://www.change.org/p/president-cyril-ramaphosa-south-africa-has-a-right-to-ivermectin

We talk with Dr. Kedar about rural research initiatives and the impact Covid-19 has had in bringing advanced research to them. Dr. Kedar specializes in autoimmune diseases that effect the musculoskeletal system, such as rheumatism, arthritis, and other disorders of the joints, muscles and ligaments. Dr. Kedar's Website: https://www.ruralamericaandcovid19.com/ Google podcasts: https://www.google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy8zZTM0NjM1Yy9wb2RjYXN0L3Jzcw== Spotify: https://open.spotify.com/show/41OxseQXTDxL8Zbru2YUNg Apple podcasts: https://podcasts.apple.com/us/podcast/rural-america-and-covid-19/id1552461945

Today we'll be touching on a tough subject, Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord.   Essentially, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves. So, what does this mean? Symptoms range from numbness or weakness one your limbs, electric-shock sensations that occur with certain neck movements, tremors, lack of coordination, and can cause visions like partial, or complete loss of vision. Melanie Rice who herself is suffering from Multiple Sclerosis. She was diagnosed Sept 20 2019 at the Mayo Clinic in Jacksonville Florida. Since then she has uncovered an entire community, or more appropriately, a family of thousands of people struggling with this autoimmune disease. She has become an advocate for MS patients, and so we have brought her on to talk with us about her illness.   Related Links: http://www.wheelchairkamikaze.com/2015/03/national-ms-society-decision-makers.html

We sit down with Sam Searcy to talk about his Company Clinistart, and innovative cloud-based service providers designed to accelerate clinical trial site activation and study start up. The goal: accelerate each step of the clinical trials process to accelerate the availability of medicines sooner for patients. You can check out Clinistart by clicking here: https://clinistart.com/

We sit down for an interview with Dr. John Boockvar, vice chair of neurosurgery at Lenox Hill Hospital, who started a first-in-human clinical research study involving a new surgical technique to treat glioblastoma multiforme (GBM) - the most aggressive form of brain cancer.   Dr. Boockvar was one of the neurosurgeons featured on the highly praised Netflix series, Lenox Hill. See link here: https://www.netflix.com/title/80201728   About the Procedure: After standard tumor resection, the patient's own scalp tissue is harvested, rotated and engrafted and used to line the resected tumor cavity. It is our hope that by doing tissue autograft, it will allow to bypass the blood brain barrier so chemotherapeutics and immune cells can better reach the tumor site, improving treatment for GBM patients. The study entitled, "Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Glioblastoma Multiforme," is being led by John Boockvar, MD, the hospital's vice chair, neurosurgery and director of Lenox Hill's Brain Tumor Center. To be eligible for the study, participants must be 18 years of age or older and plan to undergo resection of known or suspected GBM. Press release about the first patient for further background: https://www.northwell.edu/news/lenox-hill-first-to-study-using-tissue-autograft-for-gbm-tumors-in-humans Lenox Hill's neurosurgery department webpage: https://lenoxhill.northwell.edu/neurosurgery Social Media: Instagram: lhh_neurosurgery Twitter: @LenoxNeurosurg Dr. Boockvar, background link: https://www.northwell.edu/about/leadership/john-andrew-boockvar-md Dr. Boockvar's research at the Feinstein Institutes for Medical Research: https://feinstein.northwell.edu/institutes-researchers/our-researchers/john-boockvar-md

An interview with Dr. Gerald Maguire about the Phase 2 Speak Freely Study, which is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, exploratory study in adult subjects with childhood onset fluency disorder. Essentially a study directed at adults with stuttering. About Gerald A Maguire, MD, DFAPA Professor and Chair, Psychiatry and Neuroscience University of California, Riverside School of Medicine Study Link: https://speakfreely.researchstudytrial.com/ World Stuttering Network: http://www.worldstutteringnetwork.net/

We discuss "Smart" Natural Killer Cells for Cancer Treatment, Sonny Hsiao of Acepodia. A clinical trial targeting HER2-expressing solid tumors with “smart” NK cells.   Sonny Hsiao is the founder and CEO of Acepodia. Founded in 2016 the company seeks to develop new therapies in immune-oncology and cell therapy medicine. Put another way Acepodia is a novel technology platform that serves to arm immune cells with antibodies to cure cancer. Company Website: www.acepodia.com LinkedIn: https://www.linkedin.com/in/sonny-hsiao-83199956/

An Interview with Dr. Ian Smith, Founder, Director and Chief Medical Officer of Panthera Biopartners and CEO of Panthera Biopartners Stuart Young discussing the Lessons from Covid-19 and the differing strategies for recruiting and retaining patients in oncology and chronic diseases including CNS, Rheumatoid arthritis, Nash and cardiovascular. About Panthera: An independent site management organization run by a world-class team of experts, finds patients and runs clinical trials on behalf of CROs and pharma companies across multiple therapeutic areas. https://www.panthera-bio.com/ About Dr. Ian Smith: Dr. Ian founded Synexus, the world's first independent clinical trials organization, whilst practicing as a GP. He went on to build the Synexus model into the foremost SMO with sites across the world. Today Ian is a non-executive director of several healthcare companies. Ian was awarded an MBE for services to health research. About CEO Stuart Young Stuart previously managed the UK division of Synexus overseeing nine dedicated research sites. Stuart is particularly focused on the use of technology to reduce costs in clinical trials, provide a first rate patient experience and ensure that Panthera is at the cutting edge of clinical research. Stuart, holds a degree in Mechanical Engineering from University of Strathclyde in Glasgow, has had extensive experience in data management and the introduction of new technologies into organizations.

Claudia Christian of FHI Clinical discusses Covid-19 impact on Clinical Trials. The challenge of patient recruitment in Clinical Trials   Claudia Christian is the Senior Vice President, Clinical Operations of FHI Clinical. FHI Clinical has, among other things provided clinical operations services for ACTT-1 trial of remdesivir for treatment of COVID-19. Claudia Christian has held positions in pharmaceutical, biotech and CROs across multiple indications. Since 2014, she has devoted her expertise full-time to infectious disease research, including managing multiple study protocols and developing sites in support of outbreak responses. https://www.fhiclinical.com/the-elusive-covid-19-patient-subject-recruitment-remains-challenging-despite-increasing-case-numbers/

We sit down and talk to Dr. Abribat about Amolyt Pharma, which is developing therapeutic peptides to treat rare endocrine and metabolic diseases. The company recently announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its experimental therapeutic peptide, AZP-3601, for a life-altering rare disease called hypoparathyroidism. This is Amolyt's first clinical trial as a company. The trial, being conducted at sites in Europe, will test whether AZP-3601 will benefit patients with hypoparathyroidism by restoring lasting levels of calcium in their blood. Thierry Abribat, PhD can discuss why therapeutic peptides may provide better treatment options for patients with rare endocrine and metabolic diseases, the unmet need in hypoparathyroidism, AZP-360 and the ongoing trial

Dr. David Horn Solomon, CEO of Pharnext discusses PXT3003 which is currently focused on the treatment of Charcot Marie-Tooth (CMT) disease Type 1A. Charcot-Marie-Tooth is a degenerative nerve disease that usually appears in adolescence or early adulthood. CMT affects the Peripheral Nervous System. It is a progressive nerve disease. Nerves weaken over time, causing progressive disability starting in the toes and fingers and working toward the center of the body. You can visit Pharnext by clicking on this link: https://pharnext.com/ About: Dr. Solomon is a leader in the life sciences industry with a 30+ year track record. Prior to joining Pharnext, David served as the CEO of Silence Therapeutics (NASDAQ:SLN), Akari Therapeutics (NASDAQ:AKRI), Bionor Pharma (OSLO:BIONOR), and Zealand Pharma (NASDAQ:ZEAL) guiding Zealand through approval of Adlixin for Type II Diabetes. He was Managing Partner at Sund Capital in Denmark and also headed healthcare investments at Carrot Capital Healthcare Ventures in New York City. A former Board member of TxCell (acquired by Sangamo Therapeutics), Onxeo, and Promosome, David is currently Chairman of the Board for Advicenne Pharma (PARIS: ADV) and Rexgenero in London. David was earlier a Professor of Pharmacology and Neurology at Columbia University's College of Physicians and Surgeons in New York City.

Dr. Lenze discusses a clinical trial conducted by Washington University School of Medicine in St. Louis which evidences the potential that fluvoxamine, an antidepressant, may prevent COVID-19 infections from worsening. This trial is based on recent research that originates from the University of Virginia School of Medicine.   Website: https://stopcovidtrial.wustl.edu/ Phone: 314-747-1137 Email: stopcovidtrial@wustl.edu

Dr. Ragen discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma, and severe congenital neutropenia (SCN).

We sit down with Dr. CJ Barnum, Director of Neuroscience at Inmune Bio, Inc. to talk about the recently announced grant from the NIH for $2.9 million to test a new hypothesis that #neuroinflammation plays a major role in treatment resistant depression (TRD). This money will support a first-of-its-kind phase 2 study that will be conducted at two sites in the U.S. – Emory University School of Medicine in Atlanta and University of Alabama in Birmingham. Patient enrollment will be based on levels of inflammatory biomarkers and anhedonia, rather than being an all-comers study which is the standard in today's psychology trials. We also discuss INmune Bio Inc.'s developing novel therapies targeting distinct parts of the patient's immune system to fight disease. This includes drug candidates to treat #cancer, and #Alzheimers disease. To find out more about Inmune Bio Inc. you can check out there website: https://inmunebio.com/

Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn's Disease and more. https://www.abivax.com/pipeline/   - #COVID-19 https://www.abivax.com/pipeline/abx464-for-covid-19/ Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial), the unique properties of the lead candidate (antiviral, anti-inflammatory, tissue repair) to treat elderly and high-risk Covid-19 patients, the rial is ongoing in Europe and Brazil (Mexico, Peru and Chile to follow shortly) -#Cancer https://www.abivax.com/pipeline/abx196/ ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies agonists of these types of cells that demonstrate immune enhancing effects in cancer models. Preclinical data showed that ABX196 enhanced anti-tumoral activity when used alone and in combination with anti-PD1 antibodies or doxorubicin. - Ulcerative Colitis https://www.abivax.com/pipeline/abx464-ibd-uc/ ABX464 in Inflammatory Bowel Diseases (Abivax development priority), excellent two-year efficacy and safety data for ABX464 ulcerative colitis Phase 2a maintenance study and ongoing ulcerative colitis Phase 2b trial in 15 countries, the US and Canada - Crohn's disease https://www.abivax.com/pipeline/abx464-for-crohns-disease/ Planned pivotal Phase 2b/3 trial with ABX464 in Crohn's disease (FPI Q1 2021) and ngoing clinical trial with ABX464 in rheumatoid arthritis in 5 European countries - HC Ongoing clinical trial with second molecule, ABX196, in patients with hepatocellular carcinoma in the US

Dr. Negin Hajizadeh discussing Feinstein Institutes researchers finding an effective COVID-19 ‘cytokine storm' treatment and more. Dr. Hajizadeh is an ICU pulmonologist and was a part of Northwell Health's, NY largest health system, at the height of the surge. She has experienced and delivered care first hand. She is also a researcher with the Feinstein Institutes. #Recovery trial #Covid-19

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC: Dr. Pierre Kory, Associate Professor of Medicine at St. Luke's Aurora Medical Center and who TrialSite News would classify as a Pulmonologist and ICU specialist dedicated completely to the COVID-19 patient. He has been a shining light in what can be a dark and murky time in his intense commitment to treat and ensure patients are safe from this pandemic. He was educated at the St. George University Medical School at and has been board certified by the American Board of Internal Medicine in Internal Medicine, Pulmonary Disease and Critical Care Medicine. Now, Recently the topic of a TrialSite News article, Dr. Kory is an active contributor to real world-based COVID-19 protocols based on extensive, unfolding and rich evidence from the clinic during the pandemic. One alliance known as the FLCCC is a topic of discussion today.

Dr. Richard Furie discuss his recent involvement with the Phase 3 BLISS-LN clinical trial that is setting the stage for the first ever FDA approved drug for lupus nephritis. Dr. Furie is a professor at the Feinstein Institutes for medical research, Northwell Health's science arm of the health system. Regarded as one the senior rheumatologists in the New York metropolitan area, he has been on the Boards of Directors of the local chapters of the Arthritis Foundation and the Lupus Alliance of America and has been a member of the Medical-Scientific Advisory Council of the Lupus Foundation of America as well as its Lupus News editorial board. He also is on the Medical and Scientific Advisory Board of the SLE Foundation as well as the Alliance for Lupus Research Scientific Advisory Board.

We sit down with Alan Cannell, who has been a collaborator with TrialSite News down in Brazil and talk about treatments for Covid-19. An engineer by training he is originally from the Isle Of Man between Scotland and Ireland and moved to Brazil IN THE 1970s and now has a family there. He has been applying his methodical engineering mindset to studying the trends of using Ivermectin at least at the local level in Brazil.

Dr. Peter McCullough sits down to talk with TrialSite News about Pathophysiologic Rationale for Early Ambulatory Treatment for COVID-19 as an Emergency Response to the Pandemic. Dr. McCullough is board certified by the American Board of Internal Medicine in internal medicine and cardiovascular disease. He has a Masters in Public Health in Epidemiology. Dr. McCullough is an internationally recognized authority on the evaluation of medical evidence concerning contemporary issues in medicine and has published widely with more than 1000 publications and 500 citations in the National Library of Medicine. He has been a leader in the medical response to the COVID-19 disaster and has published the first guidance for the medical treatment of ambulatory patients infected with SARS-CoV-2. And, he has published a widely read OPED series on COVID-19 in TheHill. More on Dr. McCullough below: TSN Article YouTube Presentation  Baylor University Medical Center

Dr. Bruce Patterson, a decorated scientist and well-known physician as well as CEO & Co-Founder of IncellDx. Dr. Bruce Patterson talks about COVID-19 and any possible similarities between the HIV/AIDS epidemic and the SARS-COV2 virus. To learn more go here and here

Mark Erlander, Chief Executive Officer at #CardiffOncology, Inc. talks #KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal #Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here

Kathryn Ardizzone of KEI discusses COVID-19 vaccine and treatment contracts obtained by KEI from the USG under the Freedom of Information Act. The government's investment in COVID-19 vaccines and treatments. The Bayh-Dole Act and its implications for COVID-19 technologies, and efforts to get around the Bayh-Dole Act by using Other Transaction Agreements. And, the lack of transparency over federally-funded R&D.

Jason Baumgartner, a graduate from Duke University, both undergrad and MBA, has established a successful career in the world of clinical trials and drug development. In 2017 Jason founded BEKHealth Corporation. BEKHealth Corporation has advanced solutions working with health systems and their electronic medical records to support and facilitate clinical research. Jason talks with us today about the current state of research operations in a COVID world. How COVID has impacted researcher capacity. How technology is improving patient pre-screening and enrollment . How sites can implement new technologies to alleviate manual processes and see more patients. You can see more about Jason Baumgartner here

Today we have Dr. Hebbar from CalciMedica joining us today. Dr. Hebbar has 10+ years of clinical development and product development experience in both the pharmaceutical and diagnostics industries. Now, Privately held CalciMedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases. Founded in 2007 the San Diego-based company focuses on the discovery and development of CRAC channel inhibitor drugs. With the onset of the pandemic the company registered studies targeting severe COVID-19 pneumonia, a dangerous condition.

Today we welcome Roseanne Onyia Founder of a Clinical Research Organization in Nigeria called Clinique Research Development Limited. TrialSite suggested in previous writings that perhaps clinical research could represent a framework to bring together healthcare assets nationwide in a way that encourages innovation helping it to potentially leapfrog existing constraints. Ms. Onyia is the convener of  the nation's Clinical Investigators Summit bringing together key stakeholders representing clinical research to discuss the state of clinical trials in Nigeria. 

Bree Burks talks about how Clinical trials have gone through a transformation since the onset of COVID-19. Where and when possible research sponsors are moving to remote, decentralized or so-called virtual trials. She also discusses the ongoing challenges with the study start-up process and how her companies SiteVault Free eRegulatory solution for Clinical Research Sites can help. https://www.linkedin.com/in/bree-burks-78a26040/ https://www.veeva.com/

Discussion with Dr. Jordan Dubow, about addressing the unmet need in the narcolepsy treatment landscape. Dr. Dubow has an impressive track record working in research, in the clinic, in health systems, in biotech companies, an impressive array of medical and research experience with an emphasis on neurology and vascular neurology. Check out Avadel Pharmaceuticals here

We talk with Dr. Michael Brant-Zawadzki and Dr. Burton Eisenberg Hoag is First in Nation to Test Innovative Antibody Brain Cancer Drug; clinical trial for a novel immunotherapy treatment that holds considerable promise for glioblastoma (GBM), the deadliest form of brain cancer; Hoag's research and clinical trials. To learn more https://www.hoag.org/specialties-services/cancer/ To learn more about Dr. Michael Brant-Zawadzki, M.D. https://www.hoag.org/about-hoag/leadership/michael-brant-zawadzki-m-d-f-a-c-r-/ To learn more about Burton L. Eisenberg, M.D. https://www.hoag.org/specialties-services/cancer/physicians/burton-eisenberg-m-d-/

Listen as we talk to Dr. Taglietti about SCYNEXIS and their drug Ibrexafungerp The press release below talks about their successful meeting with the NDA- https://ir.scynexis.com/press-releases/detail/216/scynexis-reports-successful-completion-of-pre-nda-meetings recently for Ibrexafungerp for the treatment of VVC, the common fungal infection affecting millions of women each year in the U.S.  To view a presentation go here            

In this episode of TrialSite News Podcast we speak with Dr. Theresa Deisher about supercharging the body's own natural immune response; a potential solution to global pandemics, no-option cancers, and auto-immunity. AVM Biotechnology's lead product, AVM0703, is based on a repurposed active ingredient (Dexamethasone) approved and in use for over 60 years. Originally being researched as a precursor conditioning agent to alleviate the side effects of chemotherapy, we discovered that significantly increasing the dose of AVM's purified version induced novel natural killer T-cells (NKT), supercharged cytotoxic T-cells, and supercharged dendritic cells. The combination of these three amplified immune cells mobilized by AVM0703 show promise in aggressive cancer models. NKT cells and cytotoxic T lymphocytes are by nature programmed to kill viruses and bacteria as well as cancer. The combination of these three mobilized supercharged immune cells should kill the COVID-19-causing virus (SARS CoV2) and induce long-term. These are cells which are not normally present in circulation and are uniquely induced by AVM0703. AVM received FDA IND permission to test our lead product AVM0703 for treatment of lymphoid malignancies. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has filed with the FDA for approval to proceed with clinical trials against this virus as well as Influenza virus which also causes deadly ARDS. With a global advisory team including experts in oncology, respiratory disease, and vaccines. Fine out more about Dr. Deisher and AVM  To read more from AVM News go here 

We talk with Robert Ietswaart about drug side effects, known as adverse drug events and how AI machine learning can possible help predict these reactions. According to some reports adverse drug reactions are responsible for about 2 million U.S. hospitalizations per year reports the Department of Health and Human Services. To learn more or to reach out to Robert Ietswaart you can use the links below: LinkedIn  Harvard Medical School press release on our work Link to publication and data link to tweetorial: the whole paper explained 12 tweets

Today we have the pleasure of introducing Dr. Jean-Jacques Rajter a Broward Health Medical Center physician and his wife Dr. Juliana Cepelowicz Rajter, in Florida. We covered a story about Dr. Rajter back in April, where they were “pioneering” the use of the anti-parasitic drug ivermectin on COVID-19 patients. Today, we talk to with them both about the results from the Sunshine state, and what the future holds. Visit Dr. Rajter at http://pscflorida.com/

In this episode we speak with Dr. Raphael Stricker about PrEP, Hydroxychloroquine, and Malaria treatments for COVID-19. Dr. Raphael Stricker also does great work with Lymes Disease. Below you will find several articles on Dr. Stricker's work and more information about him overall. Lyme Disease Lyme Disease Information USMAMED Lyme Disease Mexico TrialSite News Article

In this podcast we were lucky enough to have #Dr.RogerSeheult from medcram join us here to go over a variety of topics, with a focus on #Ivermectin. Make sure yo go over and check his YouTube out as he's been following COVID-19 closely, and studies in relation to it. https://www.youtube.com/user/MEDCRAMvideos Or visit him at www.medcram.com #medcram

Below are the questions we asked Dr. Paraic Kenny about genomic sequencing and COVID-19 First before we get into COVID-19 Dr. Kenney could you tell us about yourself. It certainly is impressive that you have your own lab. Kenny Lab, What got you interested in health and medicine not to mention research?  On to COVID-19 when did you first start thinking this virus was going to be a big problem? · What was the genesis of the study to better under stand COVID-19 strains? How did you get involved with the local health department (La Cross Public Health Department)?  We know that you have international partners in this endeavor? How did this come about?  What have you learned thus far about the novel coronavirus (SARS-CoV-2)?  Dr. Kenney we have heard that there are a number of SARS-CoV-2 strains—can you update the TrialSite Network audience—how many strains of SARS-CoV-2 are there? Are some more potent or dangerous than others?  Do all the strains originate from Wuhan China? Is that conclusive?  Based on your tests and investigation has any material strategies changed there at Gunderson in relation to COVID-19 treatments?  How far along is this type of testing and analysis coming along across the United States?  What are the implications for what you have accomplished thus far?  Gunderson Health System has a great reputation—could you name three things that make it stand apart for other researchers to hear?  Any parting words of wisdom for other researchers interested in similar pursuits? Any collaborations for them to consider

In this episode Carlos Chaccour will talk about potential Ivermectin use for COVID-19, the safety of Ivermectin, potential Ivermectin use for malaria, Ivermectin use for other communicable diseases and other potential uses of ivermectin.   You can view more about Carlos Chaccour below: Carlos Chaccour -ISGlobal  The Epidemiology and Economics of Coronavirus 1  The Epidemiology and Economics of Coronavirus 2 

As director of neurology at Hudson Medical in New York Dr. Pitts heroically saved a women's life back in April during the apex of the pandemic.  Dr. Pitts connected with a mother of three and respiratory therapist who at one point was intubated for 16 days—sick with a severe to approaching critical form of COVID-19.  Thankfully through Amy de Vos doctor heard about a study involving Dr. Pitts—who included Ms. de Vos in the small emergency approved study and the rest is history.  The patient is alive today thanks to this study and clinical investigator. Listen to hear more about this situation and Dr. Pitts interested in clinical research and trials.   To find out more about Dr. Tom Pitts please see the links below:   Hudson Medical  

400 million worldwide are impacted with rare diseases and approximately 30 million in America. With organizations like Global Genes we have come quite a ways to evangelize what amounts to very vulnerable groups. In this episode Christian Rubio talks about Global Genes and how they started, their goals, and what the future looks like, especially while dealing with COVID-19. To find out more about Global Genes and Christian Rubio please see the links below: Continuity of Care RARE Patient Impact Grant programRARE Drug Development Symposium RARE List Global Genes

In this podcast Dr. Robert Jeanfreau talks about a range of specifics, from how he got involved in medicine and founded MedPharmics to MedPharmics collaboration with East Jefferson General Hospital to collect blood samples to support clinical trials addressing COVID-19 extreme cases.   You can see more information about Dr. Jeanfreau and MedPharmics here  

Ed Seguine, CEO of Clinical Ink, talks about how hybrid trials, BYOD ePRO, and DDC can provide a valuable solution during a healthcare crisis like COVID-19 You can learn more about Ed Seguine and Clinical Ink below: https://www.clinicalink.com/virtual-trials/  

Irfan Khan, M.D. talks about COVID-19 and the effect it will have on clinical trials, CROs, IROs, and research.  Dr. Khan goes over new capabilities that sites need to develop, be it virtual, home healthcare, or flexibility, and more, in order to stay competitive and keep high patient participation. Below is a summary of the questions he answers in this podcast: What is an Integrated Research Organization (IRO) and how is Circuit Clinical positioned in this space? What did Circuit do to accommodate for Trial Continuity during COVID19? Can you describe what virtual engagement means to Circuit? What can Sponsors and CRO's do to help prevent participants from dropping out of studies and improve engagement? Do research sites need a stimulus for business to continue after COVID-19? Where do you see the future in clinical research going post-COVID-19 and what changes can the industry expect? What's the best outcome that can happen post-COVID-19? What can industry stakeholders do to rescue their studies and get back on track? You can learn more about Dr. Khan and Circuit Clinical here and here  

In this podcast Craig Lipset will discuss the following: Telehealth What technologies he thinks will come out on top after COVID-19 What process changes that might be organized in the future How do you think rural healthcare will change How studies will evolve post COVID-19 And so much more You can see more about Craig Lipset below: https://www.linkedin.com/in/lipset/ https://www.youtube.com/channel/UCOixPCH4cDmCVgRP2nDLLsQ/videos https://www.youtube.com/watch?v=Ezpamq6vO_c&feature=youtu.be

Gidon Akler, MD talks about collecting samples and sequence genomes from COVID-19 patients. They hope this will help identify protective and risk bearing genetic factors, there would help in diagnostic and treatment methods. Below is a summary: The Israel Ministry of Health and the Israel Innovation Authority, along with Sourasky (Ichilov) Medical Center and Rambam Health Care Campus in addition to a startup venture called Geneyx have formed a public-private consortium that will collect samples and sequence genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the aim of identifying new diagnostic and treatment methods. The startup offers next-generation sequencing data analysis, interpretation, reporting and storage products and services. You can see more here and here 

Rich Horgan has quite a personal and unique story about how he started "Cure Rare Disease" you will want to give this podcast a listen.  Cure Rare Disease has a focus on CRISPR gene-editing therapy, and how they can improve drug development for those with rare diseases. Listen below to hear about their goal to bring various groups together to find treatments for millions of people suffering with a rare disease.  You can learn more about Rich Horgan and "Cure Rare Disease" below: Facebook: https://www.facebook.com/CureRareDisease/ Instagram: https://www.instagram.com/cureraredisease/ Twitter https://twitter.com/cureraredisease LinkedIn: https://www.linkedin.com/company/cureraredisease/

Dr. Tiwari's lab focuses on developing AI and image-analysis techniques for personalized diagnostics and therapeutic applications in Glioblastoma. In this Podcast she will discuss the implications of this work in regards to clinical trials and how it may have an impact not just as "virtual biopsies" but also for targeting radiation therapy treatments. You can find out more about Dr. Tiwari here  and here And watch more here 

In this podcast we talk with Clark Swanson of Flavocure Biotech about their flavonoid derivative of Cannabis and its demonstrations in therapeutic potential in preclinical models of metastatic pancreatic cancer. Read more here  You can see more at Flavocure.com